Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | POLQ | O75417 | 2/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18113758 | 0.89 | POLQ (0.45) | POLQP2RY1PI4KBRAF1BRAF | |
| SCHEMBL18113905 | 0.89 | RAF1 (0.38) | POLQP2RY1PI4KBRAF1BRAF | |
| SCHEMBL18113911 | 0.87 | P2RY1 (0.34) | POLQP2RY1PI4KBGRM4 | |
| SCHEMBL18113902 | 0.86 | P2RY1 (0.39) | P2RY1 | |
| SCHEMBL18113820 | 0.85 | P2RY1 (0.47) | POLQP2RY1 | |
| SCHEMBL18113812 | 0.85 | PIK3CA (0.48) | P2RY1RAF1BRAFPIK3CA | |
| SCHEMBL18113904 | 0.83 | POLQ (0.40) | POLQP2RY1PI4KBMALT1 | |
| SCHEMBL18113859 | 0.83 | ABL1 (0.41) | POLQPIK3CAMALT1 | |
| SCHEMBL18113801 | 0.83 | NCS1 (0.36) | POLQP2RY1PI4KBGRM4 | |
| SCHEMBL20481615 | 0.81 | POLQ (0.39) | POLQP2RY1GRM4PIK3CAMALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | claimed |
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | HDAC4 1077/4885HDAC6 1100/4885POLQ 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.